Immunai Inc., a New York-based artificial intelligence and biotech company specializing in mapping the human immune system, has announced a multi-year collaboration with pharmaceutical giant ...

Renovaro entered into a binding agreement merger agreement with Predictive Oncology, Inc. (“POI”) dated January 1, 2025, and supplemented with the Extension Agreement dated February 28, 2025 ...

As we stand on the brink of a technological revolution, Artificial Intelligence (AI) has emerged as a formidable ally in the fight against cancer. The convergence of AI and precision oncology is ...

Barriers to wider use of AI in oncology include inaccuracy, workflow challenges, environmental impacts, and more.

The platform uses an AI algorithm that is able to automatically analyse tissue biopsies prior to the pathologist’s review and deliver insights of whether the patient has cancer, as well as the ...

We recently published a list of Top 8 AI News Updates Driving Markets Today. In this article, we are going to take a look at where Predictive Oncology Inc. (NASDAQ:POAI) stands against other top ...

Artificial Intelligence (AI) and Machine Learning (ML) play a pivotal role in precision oncology, analyzing vast datasets, identifying patterns and aiding in informed decision-making. Within this ...

Leveraging the power of AI and machine learning technologies, researchers at Weill Cornell Medicine developed a more ...

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled "Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next ...

Renovaro Biosciences (RENB) provided an update regarding its Definitive Agreement with Predictive Oncology (POAI) to initiate the previously ...